New scandal over hormone treatment AndrocurTuesday’s Libération (p12) published an article saying a study published by French drug watchdog ANSM on the safety of Bayer's hormonal disorder treatment Androcur (cyproterone acetate) "could become the latest healthcare scandal".
Nostrum price policy under fireThursday’s Les Echos (p17) wrote about the decision of American pharmaceutical company Nostrum Pharma to raise the price of one of its drugs by more than 400%, noting that its chairman, Nirmal Mulye, had justified the move by "a moral obligation to sell its product at the highest price possible".
French pharma body elects new chairmanWednesday’s Les Echos (brief p16) and Friday’s Le Figaro (p29) reported on the election of Philippe Tcheng, a high-ranking executive at Sanofi France, to head up French pharma industry association Leem.
Executive swap for Bayer and SanofiFriday’s Les Echos (brief p20) and Le Figaro (brief p29) report that Bayer and Sanofi announced an executive swap on Thursday, with Stefan Oelrich, Sanofi's head of diabetes and cardiovascular business, succeeding Dieter Weinand as Bayer's head of pharma, while Weinand is appointed head of Sanofi's newly created primary care global business unit (APMHE 59674, APMHE 59675).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.